Does age at diagnosis influence the use of health services for multiple sclerosis?


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 13 05 2020
revised: 17 09 2020
accepted: 30 09 2020
pubmed: 13 10 2020
medline: 15 5 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

Clinical studies suggest that disease course of multiple sclerosis (MS) differs according to age of onset. However, most of these studies were cross-sectional and had modest sample sizes. Population-based administrative data provide an alternative long-term perspective on disease progression and further document the association between age at diagnosis and progression of MS. Our objective was to study the association between age at diagnosis and the use of health services for MS. Data on 1426 subjects with MS were extracted from the Québec Birth Cohort on Immunity and Health, which includes 400,611 individuals born in Québec between 1970 and 1974, followed until 2014 using administrative databases. Subjects who had ≥3 hospital or physician claims for MS during the follow-up were classified as having MS using an algorithm validated previously. Four indicators of health services use for MS were considered: number of visits to a neurologist, number of visits to a general practitioner (GP), number of visits in an emergency room and number of days of hospitalization. Generalized additive models, with a quasi-Poisson distribution were used to estimate the association between age at diagnosis and the rates of health services. Models were adjusted for the duration of follow-up, the proportion of women and the proportion of individuals who are materially and socially disadvantaged. Most subjects (76%) were women and 29% of them were between 21 and 29 years old at MS diagnosis. Subjects who were diagnosed with MS before age 29 years had a higher rate of visits to a neurologist, a higher rate of hospitalization and a lower rate of visits to a GP in the first year following MS diagnosis compared to those who were diagnosed at age 29 years or later. There were not many differences observed between subjects who had MS diagnosis before 29 years and those who had MS diagnosis at least at 29 years in the other periods of follow-up for all the indicators of health services. Although we observed some changes in the rates of visits to a neurologist and to a GP between the two diagnostic age groups, we could not conclude that age at diagnosis influences the rate of health services for MS. The use of health services allowed us to describe the association between age at diagnosis and the progression of MS at the population level.

Sections du résumé

BACKGROUND BACKGROUND
Clinical studies suggest that disease course of multiple sclerosis (MS) differs according to age of onset. However, most of these studies were cross-sectional and had modest sample sizes. Population-based administrative data provide an alternative long-term perspective on disease progression and further document the association between age at diagnosis and progression of MS. Our objective was to study the association between age at diagnosis and the use of health services for MS.
METHODS METHODS
Data on 1426 subjects with MS were extracted from the Québec Birth Cohort on Immunity and Health, which includes 400,611 individuals born in Québec between 1970 and 1974, followed until 2014 using administrative databases. Subjects who had ≥3 hospital or physician claims for MS during the follow-up were classified as having MS using an algorithm validated previously. Four indicators of health services use for MS were considered: number of visits to a neurologist, number of visits to a general practitioner (GP), number of visits in an emergency room and number of days of hospitalization. Generalized additive models, with a quasi-Poisson distribution were used to estimate the association between age at diagnosis and the rates of health services. Models were adjusted for the duration of follow-up, the proportion of women and the proportion of individuals who are materially and socially disadvantaged.
RESULTS RESULTS
Most subjects (76%) were women and 29% of them were between 21 and 29 years old at MS diagnosis. Subjects who were diagnosed with MS before age 29 years had a higher rate of visits to a neurologist, a higher rate of hospitalization and a lower rate of visits to a GP in the first year following MS diagnosis compared to those who were diagnosed at age 29 years or later. There were not many differences observed between subjects who had MS diagnosis before 29 years and those who had MS diagnosis at least at 29 years in the other periods of follow-up for all the indicators of health services.
CONCLUSION CONCLUSIONS
Although we observed some changes in the rates of visits to a neurologist and to a GP between the two diagnostic age groups, we could not conclude that age at diagnosis influences the rate of health services for MS. The use of health services allowed us to describe the association between age at diagnosis and the progression of MS at the population level.

Identifiants

pubmed: 33045495
pii: S2211-0348(20)30629-5
doi: 10.1016/j.msard.2020.102555
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102555

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Miceline Mésidor (M)

Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada; Department of Social and Preventive Medicine, Université de Montréal, Montréal, QC, Canada; Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Canada.

Marie-Pierre Sylvestre (MP)

Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada; Department of Social and Preventive Medicine, Université de Montréal, Montréal, QC, Canada.

Ruth Ann Marrie (RA)

Departments of Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Marie-Claude Rousseau (MC)

Department of Social and Preventive Medicine, Université de Montréal, Montréal, QC, Canada; Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Canada. Electronic address: marie-claude.rousseau@inrs.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH